indoximod Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
1-Methyltryptophan is a chemical compound that is an inhibitor of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase. It is a chiral compound that can exist as both D- and L-enantiomers.   Wikipedia

Chemistry

  • SMILES: Cn1cc(C[C@@H](N)C(=O)O)c2ccccc12
  • InChIKey: ZADWXFSZEAPBJS-SNVBAGLBSA-N
  • Mol. Mass: 218.26
  • ALogP: 1.13
  • ChEMBL Molecule:
    indoximod  
More Chemistry

Pharmacology

Alternative names

1-methyl-dl-trp | 1-methyl-d-tryptophan | 1-methyltryptophan | (2r)-2-amino-3-(1-methyl-1h-indol-3-yl)propanoic acid | alpha-(11c)methyl-l-tryptophan | alpha-(14c)methyl-tryptophan | alpha-methyl-l-tryptophan | alpha-methyltryptophan | alpha-methyltryptophan, (d)-isomer | alpha-methyltryptophan, (dl)-isomer | alpha-methyltryptophan, (-)-isomer | alpha-methyltryptophan, (+)-isomer | alpha-methyltryptophan, (l)-isomer | d-(+)-1-methyltryptophan | d-1-methyltryptophan | d-1mt | indoximod | nlg802

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Breast Neoplasms, Male (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Diffuse Intrinsic Pontine Glioma (Phase 2)

Ependymoma (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 1/Phase 2)

Gliosarcoma (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Lung Neoplasms (Phase 1)

Medulloblastoma (Phase 2)

Melanoma (Phase 2/Phase 3)

Neoplasms (Phase 2)

Neuroectodermal Tumors (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue